Home Special Topics Technology Offerings Content

Substances for the treatment and prophylaxis of macular degeneration

next article

13.12.2006

Age-related macular degeneration (AMD) is differentiated into a ?dry? and a ?wet? form of progression. With approx. 85 % of cases, dry AMD occurs far more often. With this form of the disease, over a period of several years, loss of light-sensitive cells in the retina occurs. One cause, amongst others, is the accumulation of a retinoid component, A2E (N-retinyl-N-retinylidene ethanolamine) in the macular region, above all in RPE cells (retinal pigment epithelial cells). That A2E induces apoptosis in RPE cells is known.<br><br> In this context, new substances are introduced which bind A2E (N-retinyl-N-retinylidene ethanolamine) and prevent the apoptosis induced by A2E in RPE cells (retinal pigment epithelial cells). These new substances are suitable for the (acute) treatment and prophylaxis of patients with dry AMD, whereby the success of the treatment can be determined easily by a decrease of lipofuscin fluorescence in the macula.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

info@technologieallianz.de | Source: TechnologieAllianz e.V.
Further information: www.technologieallianz.de/angebote.php?sort=sag&id=0829&lang=en
www.technologieallianz.de

next article